Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes compared with dipeptidyl peptidase 4 inhibitors, results of a target trial ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

1.07 to 2.02). The researchers found no consistent evidence for sex and treatment interactions with GLP-1 receptor agonists (HR, 1.17; 95% CrI, 0.87 to 1.58 for men vs women) or SGLT2 inhibitors ...

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs vs sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target trial ...